Year None2022202120202019201820172016 November 10, 2022 Medicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual Meeting Go to November 4, 2022 Medicenna Reports Second Quarter Fiscal 2023 Financial Results and Operational Highlights Go to October 28, 2022 Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Go to October 25, 2022 Medicenna to Announce Second Quarter Fiscal 2023 Financial Results and Operational Highlights on Friday, November 4, 2022 Go to October 5, 2022 Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting Go to September 30, 2022 Medicenna Extends Period to Exercise Certain Warrants Go to Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Next page next › Last page last »
November 10, 2022 Medicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual Meeting Go to
November 4, 2022 Medicenna Reports Second Quarter Fiscal 2023 Financial Results and Operational Highlights Go to
October 28, 2022 Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Go to
October 25, 2022 Medicenna to Announce Second Quarter Fiscal 2023 Financial Results and Operational Highlights on Friday, November 4, 2022 Go to
October 5, 2022 Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting Go to
